FDA approves new non-opioid painkiller made by Vertex, sending its shares higher
Vertex Pharmaceuticals’ share price rose Friday morning after the Food and Drug Administration approved its novel non-opioid painkiller, Journavx. is the first drugmaker in decades to have a non-opioi...
AbbVie climbs on new immunology drug sales
Pharmaceutical company Abbvie’s share price rose in early trading after it reported better-than-expected earnings and upbeat 2025 guidance, with newer drugs delivering growth. Overall, the company bro...
It took bird flu and dreams of AI-assisted cancer vaccines to cue Moderna’s comeback
Moderna’s share price is up 18% in the past week as it becomes increasingly clear that selling vaccines may still be a good business. The vaccine maker benefited from two recent tailwinds: a $590 mill...
Novo Nordisk stock is making serious gains after latest GLP-1 trial, which could be even better than Wegovy
Shares of surged ~11% on Friday morning after the Wegovy and Ozempic maker announced promising trial results of its experimental weight-loss drug, amycretin. Patients in the trial lost 9.7% of their ...
One of the bigger winners from “Project Stargate” is a Chinese pharmaceutical company
A wide array of biotech and pharmaceutical companies are surging on Chairman Larry Ellison’s aspirational pronouncement that spending billions on AI infrastructure has the potential to lead to person...
Moderna shoots higher on AI hopes
Moderna’s share price spiked up about 10% on Wednesday after Chairman Larry Ellison said artificial intelligence has the potential to make personalized vaccines to detect and prevent cancer. Ellison ...
J&J beats Wall Street’s estimates on cancer-meds sales
Johnson & Johnson surpassed Wall Street estimates for its last quarter of 2024 in large part because of growth in sales of its cancer-treating drugs. The company brought in $22.5 billion in revenue an...
Moderna rallies on $590 million bird flu vax grant
Moderna shot up about 7% on Tuesday morning after outgoing Health and Human Services Secretary Xavier Becerra announced a $590 million grant to the company to develop a bird flu vaccine. While bird fl...
Meds made by Novo Nordisk, Pfizer, Eli Lilly among those up for Medicare price negotiations
Ozempic is among the new slate of medications that will be subject to price negotiations for Medicare, the Department of Health and Human Services said Friday . The Inflation Reduction Act of 2022 ga...
Why Moderna and Pfizer have erased their pandemic gains
Vaccine stocks were a classic pandemic trade as investors banked on the wave of government money spent on a product the whole world desperately needed. Now, nearly five years later — has revenue rela...
Eli Lilly tumbles after selling way fewer weight-loss drugs than expected
Shares of Eli Lilly are tumbling after sales of its well-known GLP-1 weight-loss drugs massively undershot Wall Street’s expectations in the fourth quarter. The company said on Monday that it made ap...
Johnson & Johnson swallows another drugmaker in $14.6 billion deal
Johnson & Johnson announced Monday that it would acquire drugmaker Intra-Cellular Therapies for $14.6 billion, marking its latest bid for growth via swallowing a smaller company. makes Caplyta, a drug...
Moderna wipes out pandemic gains on grim 2025 sales forecast
It’s official: Moderna stock is trading like the pandemic never happened. Shares plunged in premarket trading Monday, wiping out all their pandemic-era gains after the company laid out grim sales expe...
Fundsmith dumps Diageo over weight-loss drugs
British fund manager Terry Smith is dumping its stock as it faces several headwinds, including increasingly popular weight-loss drugs. Smith’s Fundsmith, which has owned Diageo shares since it was fo...
Eli Lilly #1 in GLP-1s after Novo disappointment
Shares of are down nearly 20% in early trading on Friday, on track for their worst one-day decline since the infamous Black Monday market crash in 1987. The GLP-1 drug maker — best known for Ozempic ...
Opioid-payment report adds to healthcare stock woes
Contracts, emails, and memos spanning over two decades published in The New York Times today show how opioid makers paid key drug middlemen known as pharmacy benefit managers (PBMs) — including some s...
The obesity rate in the US fell in 2023 as GLP-1s go mainstream
Research published in the last week revealed that for the first time in more than a decade, obesity rates among US adults fell slightly last year, decreasing from 46% in 2022 to 45.6% in 2023. While w...
Vaccine stocks are tumbling on news of RFK Jr. nomination to lead HHS
Vaccine makers saw their stocks dip on Thursday following the news that President-elect Trump has nominated Robert F. Kennedy Jr. to lead the Department of Health and Human Services. Kennedy is known ...
Have Eli Lilly’s weight-loss drug gains hit a plateau?
Revenues from popular weight-loss drugs made by are flattening out. That’s disappointing to investors who were hoping for bigger gains. The company’s GLP-1 medications, Zepbound and Mounjaro, have ma...
Pfizer’s stock has almost halved since its pandemic peak, now an activist wants to shake things up
Shot in the arm Activist investor Starboard Value has built a ~$1 billion stake in Pfizer, with hopes of forcing through changes at the pharma company, according to The Wall Street Journal . Starboard...